Diadia
Our TechnologyResearchResourcesAboutLoginBook a call

© 2026 Diadia. All rights reserved.

About UsOur TechnologyResearchResourcesResearch
Privacy Policy
SupportBook a callLogin
Health Privacy Policy
InstagramFacebookLinkedInX (formerly Twitter)
Terms and Conditions
About UsOur TechnologyResearchResourcesResearch
Privacy Policy
SupportBook a callLogin
Health Privacy Policy
InstagramFacebookLinkedInX (formerly Twitter)
Terms and Conditions

© 2026 Diadia. All rights reserved.

←Transparency Reports

metabolic · Mechanism Report

Does fat tissue fatty acid release increase liver triglycerides and VLDL secretion?

Increased fatty acid release from fat tissue can promote liver triglyceride synthesis and secretion of triglyceride-rich VLDL.

PlausibleNovember 18, 20269 Sources

Reasoning Paths

Each route from condition to outcome carries a support score — the product of its edge weights. Select one to isolate it on the figure.

This is what AI claimed

Increased release of free fatty acids from adipose tissue delivers more substrate to the liver, promoting hepatic triglyceride synthesis and triglyceride-rich very-low-density lipoprotein secretion.

laying out figure…
1 of 5 paths supported
UnsupportedPlausibleSupported

How to read the figure

Evidence state

  • ●EstablishedStrong, replicated evidence.
  • ◐ModerateEvidence-informed; limited or moderate.
  • ◇PlausibleMechanistically coherent, not established.
  • ✕UnsupportedTested and not supported — link breaks.
  • ?MissingNo evidence either way — untested.

Node shapes

  • BiomarkerA measurable state — a lab value, hormone, or genetic factor.
  • ProcessA biological process, pathway, or mechanism step.
  • ConditionA condition, exposure, intervention, or symptom.
  • OutcomeThe endpoint the claim leads to.

Executive summary

Fatty acids released from fat tissue provide substrate for triglyceride synthesis in the liver. Triglycerides support VLDL assembly, although the magnitude of secretion varies and does not necessarily reflect an increase in particle number.

Verified conclusion

Increased adipose-tissue lipolysis is a biologically and clinically credible contributor to hepatic triglyceride accumulation and export in VLDL. The overall pathway is supported by human flux and tracer studies, direct experimental evidence for substrate-driven esterification, and established VLDL-assembly biology, although the magnitude of each step is context-dependent.

Clinical and metabolic evidence

  • Human isotope-tracer and hepatic-vein studies indicate that adipose-derived free fatty acids (FFAs) provide most circulating FFAs and much of the fatty-acid substrate delivered to liver. Visceral lipolysis contributes through the portal circulation; in obesity, estimated splanchnic contributions ranged from <10% to nearly 50% of hepatic FFA delivery and increased with visceral adiposity.
  • In obesity/NAFLD, plasma non-esterified fatty acids accounted for an estimated 59% of liver triglyceride fatty acids, versus 26% from de novo lipogenesis and 15% from dietary fat. These proportions are not universal, but demonstrate the major precursor role of circulating FFAs in this setting.
  • Increased lipid availability can translate into greater VLDL-triglyceride output. Extreme carbohydrate overfeeding increased VLDL-triglyceride secretion approximately 3.4-fold by day 4, accompanying increased secretion of de-novo-lipogenesis–derived fatty acids.

Mechanistic interpretation

  • Experimental fatty-acid elevation increases hepatic esterification into triglyceride; in isotope-tracer rat experiments, this occurred independently of insulin.
  • Hepatic triglyceride availability supports VLDL assembly: microsomal triglyceride transfer protein (MTP) lipidates nascent apoB100, preventing apoB degradation and enabling secretion of triglyceride-rich particles.
  • This does not necessarily mean more VLDL particles. ApoB100 secretion explained only about 30% of variation in VLDL-triglyceride secretion in one human study, consistent with increased triglyceride cargo per particle.

Bottom line

  • The claim is supported: greater adipose FFA release—especially with visceral adiposity—raises hepatic fatty-acid substrate availability, promotes triglyceride synthesis, and can increase secretion of triglyceride-rich VLDL. The response depends on insulin resistance, hepatic lipid stores, MTP/apoB assembly capacity, and VLDL clearance.

References

  1. Splanchnic lipolysis in human obesity - JCI — jci.org ↗
  2. Is Visceral Fat Involved in the Pathogenesis of the Metabolic Syndrome? Human Model — onlinelibrary.wiley.com ↗
  3. Splanchnic lipolysis in human obesity — pmc.ncbi.nlm.nih.gov ↗
  4. Insulin-independent regulation of hepatic triglyceride synthesis by fatty acids | PNAS — pnas.org ↗
  5. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease — pmc.ncbi.nlm.nih.gov ↗
  6. Contributions of de novo synthesis of fatty acids to total VLDL-triglyceride secretion during prolonged hyperglycemia/hyperinsulinemia in normal man — pmc.ncbi.nlm.nih.gov ↗
  7. VLDL Biogenesis and Secretion: It Takes a Village - PMC — pmc.ncbi.nlm.nih.gov ↗
  8. Increased Very Low Density Lipoprotein Secretion, ... - PMC — pmc.ncbi.nlm.nih.gov ↗
  9. VLDL Triglyceride Kinetics in Lean, Overweight, and Obese Men and Women — pmc.ncbi.nlm.nih.gov ↗

See a full patient report verified like this

Book a walkthrough

Related Claims

Plausible2 sourcesCan disrupted sleep and circadian rhythms contribute to insulin resistance?→Plausible4 sourcesCan sustained cortisol excess contribute to insulin resistance?→